Page:United States Statutes at Large Volume 117.djvu/2341

 117 STAT. 2322

Deadline.

PUBLIC LAW 108–173—DEC. 8, 2003

days after the date of the enactment of this Act, but in no case may the project extend beyond December 31, 2005. (d) LIMITATION.—Under the demonstration project over the duration of the project, the Secretary may not provide— (1) coverage for more than 50,000 patients; and (2) more than $500,000,000 in funding. (e) REPORT.—Not later than July 1, 2006, the Secretary shall submit to Congress a report on the project. The report shall include an evaluation of patient access to care and patient outcomes under the project, as well as an analysis of the cost effectiveness of the project, including an evaluation of the costs savings (if any) to the medicare program attributable to reduced physicians’ services and hospital outpatient departments services for administration of the biological. SEC. 642. EXTENSION OF COVERAGE OF INTRAVENOUS IMMUNE GLOBULIN (IVIG) FOR THE TREATMENT OF PRIMARY IMMUNE DEFICIENCY DISEASES IN THE HOME.

(a) IN GENERAL.—Section 1861 (42 U.S.C. 1395x), as amended by sections 611(a) and 612(a) is amended— (1) in subsection (s)(2)— (A) by striking ‘‘and’’ at the end of subparagraph (X); (B) by adding ‘‘and’’ at the end of subparagraph (Y); and (C) by adding at the end the following new subparagraph: ‘‘(Z) intravenous immune globulin for the treatment of primary immune deficiency diseases in the home (as defined in subsection (zz));’’; and (2) by adding at the end the following new subsection: ‘‘Intravenous Immune Globulin

42 USC 1395l note.

‘‘(zz) The term ‘intravenous immune globulin’ means an approved pooled plasma derivative for the treatment in the patient’s home of a patient with a diagnosed primary immune deficiency disease, but not including items or services related to the administration of the derivative, if a physician determines administration of the derivative in the patient’s home is medically appropriate.’’. (b) PAYMENT AS A DRUG OR BIOLOGICAL.—Section 1833(a)(1)(S) (42 U.S.C. 1395l(a)(1)(S)) is amended by inserting ‘‘(including intravenous immune globulin (as defined in section 1861(zz)))’’ after ‘‘with respect to drugs and biologicals’’. (c) EFFECTIVE DATE.—The amendments made by this section shall apply to items furnished administered on or after January 1, 2004. SEC.

Deadline. 42 USC 1395x note.

VerDate 11-MAY-2000

13:59 Aug 30, 2004

643.

MEDPAC STUDY OF COVERAGE OF SURGICAL FIRST ASSISTING SERVICES OF CERTIFIED REGISTERED NURSE FIRST ASSISTANTS.

(a) STUDY.—The Medicare Payment Advisory Commission (in this section referred to as the ‘‘Commission’’) shall conduct a study on the feasibility and advisability of providing for payment under part B of title XVIII of the Social Security Act for surgical first assisting services furnished by a certified registered nurse first assistant to medicare beneficiaries. (b) REPORT.—Not later than January 1, 2005, the Commission shall submit to Congress a report on the study conducted under

Jkt 019194

PO 00000

Frm 00258

Fmt 6580

Sfmt 6581

D:\STATUTES\2003\19194PT3.001

APPS10

PsN: 19194PT3

�